“…Current regimens for patients with metastatic CRC include anti-EGFR monoclonal antibodies such as cetuximab and panitumumab, both functioning to block the binding of ligands to EGFR, thereby downregulating ERK/MAPK and PI3K/PTEN/AKT pathway signalling (Amado et al, 2008;Giusti et al, 2008;Segal and Saltz, 2009). New evidence suggests that patients with KRAS, BRAF or PTEN mutations experience fewer clinical responses to these drugs, compared with patients with wild-type tumours; moreover, molecular analysis, particularly of KRAS, is routinely being performed in standard molecular pathology laboratories (Lievre et al, 2006;Amado et al, 2008;Di Nicolantonio et al, 2008;Karapetis et al, 2008;Au et al, 2009;Jimeno et al, 2009;Sartore-Bianchi et al, 2009).…”